Axovant focuses on compounds that may offer life-changing promise for patients. Each compound has the potential to improve the cognitive, functional, and behavioral aspects of neurologic disorders.
AXO-Lenti-PD is an investigational gene therapy for Parkinson’s disease that delivers three genes encoding a critical set of enzymes required for dopamine synthesis in the brain.
Nelotanserin is a potent and highly selective inverse agonist of the 5HT2A receptor.
RVT-104 is potential therapy for patients with Alzheimer's disease and dementia with Lewy bodies.